ClinicalTrials.govpublic full text
Is Prolonged Systemic Immunotherapy Necessary After Achieving Tumor-free Status in Patients With Extensive Transurethrally Unresectable Very-high-risk NMIBC?
bladder (urothelial, transitional cell) cancer, non muscle invasive bladder cancer, non-muscle-invasive bladder cancer (nmibc), liquid biopsy, immunotherapy, interventional, phase2
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Related documents
Record · ID 834389
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.